highly significantP < 0.001
KRAS codon 13 polymorphisms were identified in 21.4% of iCCA patients, were absent in OV cases, and were present in 17.5% of healthy controls, demonstrating a highly significant difference (P < 0.001).
KRAS codon 13 polymorphisms were identified in 21.4% of iCCA patients, were absent in OV cases, and were present in 17.5% of healthy controls, demonstrating a highly significant difference (P < 0.001).
Furthermore, ordinal regression analysis used to predict tumor stage indicated that metastasis was the only highly significant factor (P < 0.001), while tumor size showed a trend toward significance (P = 0.068). 3.5.